Efficiency of combination therapy with mebeverine and psyllium in patients with irritable bowel syndrome with predominant constipation
https://doi.org/10.21518/ms2025-344
Abstract
Introduction. Irritable bowel syndrome (IBS) is one of the most pressing problems in gastroenterology, approaches to its treatment are rapidly changing.
Aim. To study the efficacy of mebeverine and psyllium therapy in IBS patients with predominant constipation (IBS-C).
Materials and methods. A total of 177 patients with IBS-C were examined. The patients were divided into 4 groups: Group A – 42 patients received psyllium 30 g per day for 8 weeks; Group B – 48 patients received Mebeverine 400 mg per day for 4 weeks; Group C – 49 patients were treated with Mebeverine 400 mg per day for 8 weeks; Group D – 38 patients received Mebeverine 400 mg per day and psyllium 30 g per day for 8 weeks. IBS was diagnosed based on Rome IV criteria. Patients were examined with clinical data recorded every 2 weeks for 8 weeks.
Results. According to the IBS-SSS scale, in group C the total score decreased during therapy from 259 to 49 points, in group D – from 240 to 33 points (in both groups p = 0.001; рC/D = 0,36). The study of the dynamics of stool frequency and form over 8 weeks demonstrated the significant effectiveness of psyllium. The frequency of stool increased in group A from 1.6 to 4.8 times per week (p = 0.01), in group D – from 1.5 to 5.5 times per week (p = 0.03). In patients of groups B and C, such obvious positive changes in the frequency and form of stool were not recorded.
Conclusion. The combination of mebeverine and psyllium in patients with IBS-C, used for 8 weeks, showed good results and made it possible to relieve both the manifestations of pain syndrome and improve intestinal motility indicators.
About the Authors
V. V. Tsukanov
Federal Research Center “Krasnoyarsk Science Center of the Siberian Branch of the Russian Academy of Sciences”, Research Institute of Medical Problems of the North
Russian Federation
Russian Federation
Vladislav V. Tsukanov, Dr. Sci. (Med.), Professor, Head of the Clinical Department of the Digestive System Pathology of Adults and Children
3g, Partizan Zheleznyak St., Krasnoyarsk, 660022
M. A. Cherepnin
Federal Research Center “Krasnoyarsk Science Center of the Siberian Branch of the Russian Academy of Sciences”, Research Institute of Medical Problems of the North
Russian Federation
Russian Federation
Mikhail A. Cherepnin, Junior Researcher of the Clinical Department of the Digestive System Pathology of Adults and Children
3g, Partizan Zheleznyak St., Krasnoyarsk, 660022
J. L. Tonkikh
Federal Research Center “Krasnoyarsk Science Center of the Siberian Branch of the Russian Academy of Sciences”, Research Institute of Medical Problems of the North
Russian Federation
Russian Federation
Julia L. Tonkikh, Cand. Sci. (Med.), Leading Researcher of the Clinical Department of the Digestive System Pathology of Adults and Children
3g, Partizan Zheleznyak St., Krasnoyarsk, 660022
A. V. Vasyutin
Federal Research Center “Krasnoyarsk Science Center of the Siberian Branch of the Russian Academy of Sciences”, Research Institute of Medical Problems of the North
Russian Federation
Russian Federation
Alexander V. Vasyutin, Cand. Sci. (Med.), Senior Researcher of the Clinical Department of the Digestive System Pathology of Adults and Children
3g, Partizan Zheleznyak St., Krasnoyarsk, 660022
References
1. Drossman DA, Hasler WL. Rome IV – Functional GI Disorders: Disorders of Gut-Brain Interaction. Gastroenterology. 2016;150(6):1257–1261. https://doi.org/10.1053/j.gastro.2016.03.035.
2. Lacy BE, Mearin F, Chang L, Chey WD, Lembo AJ, Simren M, Spiller R. Bowel Disorders. Gastroenterology. 2016;150(6):1393–1407. https://doi.org/10.1053/j.gastro.2016.02.031.
3. Jaafari H, Houghton LA, West RM, Agrawal A, Aziz I, Black CJ et al. The national prevalence of disorders of gut brain interaction in the United Kingdom in comparison to their worldwide prevalence: Results from the Rome foundation global epidemiology study. Neurogastroenterol Motil. 2023;35(6):e14574. https://doi.org/10.1111/nmo.14574.
4. Oka P, Parr H, Barberio B, Black CJ, Savarino EV, Ford AC. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(10):908–917. https://doi.org/10.1016/S2468-1253(20)30217-X.
5. Vasant DH, Paine PA, Black CJ, Houghton LA, Everitt HA, Corsetti M et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut. 2021;70(7):1214–1240. https://doi.org/10.1136/gutjnl-2021-324598.
6. Chang L, Sultan S, Lembo A, Verne GN, Smalley W, Heidelbaugh JJ. AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation. Gastroenterology. 2022;163(1):118–136. https://doi.org/10.1053/j.gastro.2022.04.016.
7. Ivashkin VT, Maev IV, Shelygin YuA, Baranskaya EK, Belous SS, Belousova EA et al. Diagnosis and Treatment of Irritable Bowel Syndrome: Clinical Recommendations of the Russian Gastroenterological Association and Association of Coloproctologists of Russia. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(5):74–95. (In Russ.) https://doi.org/10.22416/1382-4376-2021-31-5-74-95.
8. Brenner DM, Lacy BE. Antispasmodics for Chronic Abdominal Pain: Analysis of North American Treatment Options. Am J Gastroenterol. 2021;116(8):1587–1600. https://doi.org/10.14309/ajg.0000000000001266.
9. van der Schoot A, Drysdale C, Whelan K, Dimidi E. The Effect of Fiber Supplementation on Chronic Constipation in Adults: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials. Am J Clin Nutr. 2022;116(4):953–969. https://doi.org/10.1093/ajcn/nqac184.
10. Ivashkin VT, Shelygin YuA, Maev IV, Sheptulin AA, Aleshin DV, Achkasov SI et al. Clinical Recommendations of the Russian Gastroenterological Association and Association of Coloproctologists of Russia on Diagnosis and Treatment of Constipation in Adults. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(6):69–85. (In Russ.) https://doi.org/10.22416/1382-4376-2020-30-6-69-85.
11. Enck P, Aziz Q, Barbara G, Farmer AD, Fukudo S, Mayer EA et al. Irritable bowel syndrome. Nat Rev Dis Primers. 2016;2:16014. https://doi.org/10.1038/nrdp.2016.14.
12. Bengtsson M, Ohlsson B, Ulander K. Development and psychometric testing of the Visual Analogue Scale for Irritable Bowel Syndrome (VAS-IBS). BMC Gastroenterol. 2007;7:16. https://doi.org/10.1186/1471-230X-7-16.
13. Mujagic Z, Keszthelyi D, Aziz Q, Reinisch W, Quetglas EG, De Leonardis Fet al. Systematic review: instruments to assess abdominal pain in irritable bowel syndrome. Aliment Pharmacol Ther. 2015;42(9):1064–1081. https://doi.org/10.1111/apt.13378.
14. Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997;11(2):395–402. https://doi.org/10.1046/j.1365-2036.1997.142318000.x.
15. Arif TB, Ali SH, Bhojwani KD, Sadiq M, Siddiqui AA, Ur-Rahman A et al. Global prevalence and risk factors of irritable bowel syndrome from 2006 to 2024 using the Rome III and IV criteria: a meta-analysis. Eur J Gastroenterol Hepatol. 2025. https://doi.org/10.1097/MEG.0000000000002994.
16. Valitutti F, Mennini M, Monacelli G, Fagiolari G, Piccirillo M, Di Nardo G, Di Cara G. Intestinal permeability, food antigens and the microbiome: a multifaceted perspective. Front Allergy. 2025;5:1505834. https://doi.org/10.3389/falgy.2024.1505834.
17. Grover M, Vanuytsel T, Chang L. Intestinal Permeability in Disorders of GutBrain Interaction: From Bench to Bedside. Gastroenterology. 2025;168(3):480–495. https://doi.org/10.1053/j.gastro.2024.08.033.
18. Ford AC, Staudacher HM, Talley NJ. Postprandial symptoms in disorders of gut-brain interaction and their potential as a treatment target. Gut. 2024;73(7):1199–1211. https://doi.org/10.1136/gutjnl-2023-331833.
19. Bhagavathula AS, Al Qady AM, Aldhaleei WA. Diagnostic accuracy and quality of artificial intelligence models in irritable bowel syndrome: A systematic review. World J Gastroenterol. 2025;31(23):106836. https://doi.org/10.3748/wjg.v31.i23.106836.
20. Camilleri M, Ford AC. Review Article: Surrogate Endpoints to Assess Treatment Efficacy in Disorders of Gut-Brain Interaction of Lower Gastrointestinal Tract. Aliment Pharmacol Ther. 2025;61(6):950–958. https://doi.org/10.1111/apt.18527.
21. Khasawneh M, Mokhtare M, Moayyedi P, Black CJ, Ford AC. Efficacy of gutbrain neuromodulators in irritable bowel syndrome: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2025;10(6):537–549. https://doi.org/10.1016/S2468-1253(25)00051-2.
22. Choi Y, Youn YH, Kang SJ, Shin JE, Cho YS, Jung YS et al. 2025 Seoul Consensus on Clinical Practice Guidelines for Irritable Bowel Syndrome. J Neurogastroenterol Motil. 2025;31(2):133–169. https://doi.org/10.5056/jnm25007.
23. Goodoory VC, Khasawneh M, Thakur ER, Everitt HA, Gudleski GD, Lackner JM et al. Effect of Brain-Gut Behavioral Treatments on Abdominal Pain in Irritable Bowel Syndrome: Systematic Review and Network MetaAnalysis. Gastroenterology. 2024;167(5):934–943.e5. https://doi.org/10.1053/j.gastro.2024.05.010.
24. Black CJ, Ford AC. An evidence-based update on the diagnosis and management of irritable bowel syndrome. Expert Rev Gastroenterol Hepatol. 2025;19(23):227–242. https://doi.org/10.1080/17474124.2025.2455586.
25. Busam JA, Batta N, Shah ED, Joo L, Marshall C, Rezaie A, Pimentel M. The Safety of Pharmacotherapy for Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2025. https://doi.org/10.14309/ajg.0000000000003572.
26. Ruepert L, Quartero AO, de Wit NJ, van der Heijden GJ, Rubin G, Muris JW. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2011;2011(8):CD003460. https://doi.org/10.1002/14651858.CD003460.pub3.
27. Hou X, Chen S, Zhang Y, Sha W, Yu X, Elsawah H et al. Quality of life in patients with Irritable Bowel Syndrome (IBS), assessed using the IBSQuality of Life (IBS-QOL) measure after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: results of an international prospective observational cohort study in Poland, Egypt, Mexico and China. Clin Drug Investig. 2014;34(11):783–793. https://doi.org/10.1007/s40261-014-0233-y.
Review
For citations:
Tsukanov VV, Cherepnin MA, Tonkikh JL, Vasyutin AV. Efficiency of combination therapy with mebeverine and psyllium in patients with irritable bowel syndrome with predominant constipation. Meditsinskiy sovet = Medical Council. 2025;19(13):133-139. (In Russ.) https://doi.org/10.21518/ms2025-344
Views:
55
Email this article 